In the phase Ib, taselisib (supplied by Genentech, Inc.) was administered orally at a starting dose of 2 mg and escalated to 4 mg, 6 mg and 8 mg in a 3+3 trial design. This was in combination with 160 mg enzalutamide (supplied by Astellas Pharma, US) taken daily orally without interruption for a 28-day cycle. Patients were treated until disease progression or unacceptable toxicity. In phase II, patients received either 160 mg enzalutamide alone or 160 mg enzalutamide in combination with 4 mg taselisib orally, as prior phase I single agent testing of taselisib showed activity at 4 mg(21 (link)).
Protocol detail
Taselisib and Enzalutamide for Prostate Cancer
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization : Vanderbilt University Medical Center
Other organizations : Dana-Farber Cancer Institute, Mayo Clinic, University of Chicago, University of Michigan–Ann Arbor, Indiana University – Purdue University Indianapolis, Baylor College of Medicine, The University of Texas Southwestern Medical Center, Johns Hopkins University
Top 5 similar protocols
Variable analysis
independent variables
- Taselisib dose (2 mg, 4 mg, 6 mg, 8 mg)
- Enzalutamide (160 mg) in combination with taselisib
- Disease progression
- Unacceptable toxicity
- Enzalutamide dose (160 mg) taken daily orally without interruption for a 28-day cycle
- Prior phase I single agent testing of taselisib showed activity at 4 mg
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!